Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum

Parasitology Research

Volumn 113, Issue 5, 2014, Pages 1875-1881

  Hendrickx, S ^a   Boulet, G ^a   Mondelaers, A ^a   Dujardin, J C ^a,b   Rijal, S ^c   Lachaud, L ^d   Cos, P ^a   Delputte, P ^a   Maes, L ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Giemsa; In vitro; Promastigote back transformation

Indexed keywords

MILTEFOSINE; PAROMOMYCIN;

AMASTIGOTE; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GIEMSA STAIN; IC 50; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; NONHUMAN; PARASITE CULTIVATION; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; LEISHMANIA DONOVANI; MACROPHAGES; MICE; PARASITIC SENSITIVITY TESTS; PAROMOMYCIN; PHOSPHORYLCHOLINE;

EID: 84901381712     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-014-3835-7     Document Type: Article

References (27)

1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5:873-882
2. Cojean S, Houze S, Haouchine D, Huteau F, Lariven S, Hubert V, Michard F, Bories C, Pratlong F, Le BJ, Loiseau PM, Matheron S (2012) Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis 18:704-706
3. Davidson RN, den Boer M, Ritmeijer K (2009) Paromomycin. Trans R Soc Trop Med Hyg 103:653-660
4. Dhillon GP, Sharma SN, Nair B (2008) Kala-azar elimination programme in India. J Indian Med Assoc 106(664):664-666, 668
5. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67:2576-2597
6. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, De DS, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schonian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M (2011) Whole genome sequencing ofmultiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res
7. Frezard F, Demicheli C, Ribeiro RR (2009) Pentavalent antimonials: new perspectives for old drugs. Molecules 14:2317-2336
8. Garcia-Hernandez R, Manzano JI, Castanys S, Gamarro F (2012) Leishmania donovani develops resistance to drug combinations. PLoS Negl Trop Dis 6:e1974
9. Hendrickx S, I da Luz RA, Bhandari V, Kuypers K, Shaw CD, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L (2012) Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl Trop Dis 6:e1664
10. Inocencio da Luz RA, Vermeersch M, Deschacht M, Hendrickx S, Van AT, Cos P, Maes L (2011) In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species. J Antimicrob Chemother 66:350-353
11. Inocencio da Luz RA, Vermeersch M, Dujardin JC, Cos P, Maes L (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53:5197-5203
12. Jeddi F, Piarroux R, Mary C (2011) Antimony resistance in Leishmania, focusing on experimental research. J Trop Med 2011:695382
13. Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P (2013) Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res 112:825-828
14. Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M (1998) Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 5:167-173
15. Maes L, Cos P, Croft S (2013) The relevance of susceptibility tests, breakpoints and markers. In: Ponte-Sucre A, Diaz E, Padrón-Nieves M (eds) Drug Resistance in Leishmania Parasites. Springer, Vienna, pp 407-429
16. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727-737
17. Quispe Tintaya KW, Ying X, Dedet JP, Rijal S, De Bolle X, Dujardin JC (2004) Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. J Infect Dis 189:1035-1043
18. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC (2013) Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56:1530-1538
19. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22:380-387
20. Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849-854
21. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739-1746
22. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (2007) Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356:2571-2581
23. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G (2008) Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal - the challenges for diagnosis and treatment. Trop Med Int Health 13:2-5
24. Sundar S, Olliaro PL (2007)Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3:733-740
25. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55:543-550
26. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10:184-194
27. Vermeersch M, Inocencio da Luz RA, Tote K, Timmermans JP, Cos P, Maes L (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53:3855-3859